OBJECTIVE: The aim of the study was to determine the incidence of myocardial dysfunction in an HIV-infected population receiving state-of-the-art treatment. METHODS: Between April 2001 and July 2002, 91 HIV-infected patients had a radionuclide ventriculography performed with determination of right ventricular ejection fraction (RVEF) and left ventricular ejection fraction (LVEF), as well as measurement of brain natriuretic peptide (BNP). Between July 2005 and January 2007, 63 patients (69%) agreed to participate in a follow-up study with a mean follow-up of 4.5 years. RESULTS: All patients had normal LVEF at both examinations. A minimal increase in mean LVEF of 0.02 was observed at follow-up (P=0.01). At the initial visit, four patients [6%; 95% confidence interval (CI) 2-15%] had a reduced RVEF, and at follow-up two patients (3%; 95% CI 0-11%) had slightly reduced RVEF. No significant change in mean RVEF was found. No patients had increased BNP and no change in mean plasma BNP was found. CONCLUSIONS: HIV-related cardiomyopathy appears not to constitute a problem in closely monitored, well-treated HIV-infected patients. Compared with pre-highly active antiretroviral therapy (HAART) studies, it seems that the improvement in immunocompetency and viral load has removed the problem of HIV-related cardiomyopathy. Although HAART has been suggested as a possible new cause of cardiomyopathy, we did not find any evidence of this.
OBJECTIVE: The aim of the study was to determine the incidence of myocardial dysfunction in an HIV-infected population receiving state-of-the-art treatment. METHODS: Between April 2001 and July 2002, 91 HIV-infectedpatients had a radionuclide ventriculography performed with determination of right ventricular ejection fraction (RVEF) and left ventricular ejection fraction (LVEF), as well as measurement of brain natriuretic peptide (BNP). Between July 2005 and January 2007, 63 patients (69%) agreed to participate in a follow-up study with a mean follow-up of 4.5 years. RESULTS: All patients had normal LVEF at both examinations. A minimal increase in mean LVEF of 0.02 was observed at follow-up (P=0.01). At the initial visit, four patients [6%; 95% confidence interval (CI) 2-15%] had a reduced RVEF, and at follow-up two patients (3%; 95% CI 0-11%) had slightly reduced RVEF. No significant change in mean RVEF was found. No patients had increased BNP and no change in mean plasma BNP was found. CONCLUSIONS: HIV-related cardiomyopathy appears not to constitute a problem in closely monitored, well-treated HIV-infectedpatients. Compared with pre-highly active antiretroviral therapy (HAART) studies, it seems that the improvement in immunocompetency and viral load has removed the problem of HIV-related cardiomyopathy. Although HAART has been suggested as a possible new cause of cardiomyopathy, we did not find any evidence of this.
Authors: Adeel A Butt; Chung-Chou Chang; Lewis Kuller; Matthew Bidwell Goetz; David Leaf; David Rimland; Cynthia L Gibert; Krisann K Oursler; Maria C Rodriguez-Barradas; Joseph Lim; Lewis E Kazis; Stephen Gottlieb; Amy C Justice; Matthew S Freiberg Journal: Arch Intern Med Date: 2011-04-25
Authors: Ather Mansoor; Keri Althoff; Stephen Gange; Kathryn Anastos; Jack Dehovitz; Howard Minkoff; Robert Kaplan; Susan Holman; Jason M Lazar Journal: AIDS Res Hum Retroviruses Date: 2009-10 Impact factor: 2.205
Authors: Daniel A Duprez; Jacqueline Neuhaus; Russell Tracy; Lewis H Kuller; Steven G Deeks; Chloe Orkin; Albrecht Stoehr; Ian J Woolley; James D Neaton Journal: AIDS Date: 2011-03-13 Impact factor: 4.177
Authors: Matthew R Gingo; Yingze Zhang; Kidane B Ghebrehawariat; Jong-Hyeon Jeong; Yanxia Chu; Quanwei Yang; Lorrie Lucht; David B Hanna; Jason M Lazar; Mark T Gladwin; Alison Morris Journal: PLoS One Date: 2015-03-26 Impact factor: 3.240
Authors: Andrew W McCrary; Winstone M Nyandiko; Alicia M Ellis; Hrishikesh Chakraborty; Michael J Muehlbauer; Myra M Koech; Ibrahim Daud; Elcy Birgen; Nathan M Thielman; Joseph A Kisslo; Piers C A Barker; Gerald S Bloomfield Journal: AIDS Date: 2020-03-15 Impact factor: 4.632